Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 404 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disease, Bacterial Clear all
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01290341
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 (naftin 2 % gel), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

NCT05849922
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Ocala, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 7, 2026, 1:40 AM EDT
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01270971
View directory record Official record
Conditions
Onychomycosis of Toenails
Interventions
AN2690 Topical Solution, 5%, Solution Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Burbank, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Not applicable Interventional Results available

Individualized vs. Household MRSA Decolonization

NCT01814371
View directory record Official record
Conditions
Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
Drug · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

NCT02812771
View directory record Official record
Conditions
Onychomycosis
Interventions
Efinaconazole
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT05819398
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 3 Interventional

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

NCT00303550
View directory record Official record
Conditions
Skin Diseases, Bacterial
Interventions
Intravenous iclaprim, Intravenous linezolid
Drug
Lead sponsor
Arpida AG
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Naperville, Illinois • Casper, Wyoming
Source: ClinicalTrials.gov public record
Updated Mar 27, 2007 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

NCT00555061
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Ointment, 1%
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Months to 24 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Tuscaloosa, Alabama • Bentonville, Arkansas • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Not applicable Interventional Results available

Wound Dressings for Hidradenitis Suppurativa

NCT04194541
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Cutimed Sorbact Hydroactive B wound dressing, Cutimed Siltect wound dressing, Sorbion Sana multi-star wound dressing
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 7, 2026, 1:40 AM EDT
Terminated No phase listed Observational

Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing

NCT03271580
View directory record Official record
Conditions
Wound, Bacterial Infections, Diabetes Mellitus, Infected Ulcer of Skin
Interventions
Finger prick test for HbA1c measurement, Punch Biopsy, Vac Sponge Collection, Ankle Brachial Index
Diagnostic Test · Procedure · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

NCT00289588
View directory record Official record
Conditions
Community-Acquired MRSA Infections, Abscesses, Cellulitis, Folliculitis
Interventions
Mupirocin (drug)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
17 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2006 · Synced Oct 7, 2026, 1:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Not applicable Interventional

Evaluating Blast-X® in Combination With Negative Pressure Wound Therapy

NCT04265170
View directory record Official record
Conditions
Pressure Ulcer
Interventions
BlastX with negative pressure therapy
Device
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kittanning, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 7, 2026, 1:40 AM EDT
Not yet recruiting No phase listed Observational

An Observational Study of Patients With Dermatologic Disease

NCT07748169
View directory record Official record
Conditions
Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
2,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 7, 2026, 1:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

NCT00867269
View directory record Official record
Conditions
Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis, Warts
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 7, 2026, 1:40 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees

NCT01105767
View directory record Official record
Conditions
Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections
Interventions
Chlorhexidine gluconate, Supplemental training, education and hygiene
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 42 Years · Male only
Enrollment
30,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 7, 2026, 1:40 AM EDT
Completed No phase listed Observational

Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

NCT02060513
View directory record Official record
Conditions
Infection, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
Interventions
Not listed
Lead sponsor
Connie Price
Other
Eligibility
18 Years and older
Enrollment
2,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Denver, Colorado • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Not applicable Interventional

Pulsed Dye Laser Treatment of Onychomycosis

NCT01915355
View directory record Official record
Conditions
Onychomycosis
Interventions
Pulsed Dye Laser for the treatment of nail fungus
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cumulative Irritation Test

NCT00781664
View directory record Official record
Conditions
Tinea Pedis
Interventions
AN2718, AN2718, Sodium Lauryl Sulfate
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 7, 2026, 1:40 AM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

NCT06555328
View directory record Official record
Conditions
Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
Interventions
CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment, HS low dose treatment, HS medium dose treatment, HS high dose treatment
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • North Miami Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Retapamulin Microdialysis Feasibility Study

NCT01812382
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Microdialysis
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 7, 2026, 1:40 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

NCT01431820
View directory record Official record
Conditions
Distal and Lateral Subungual Onychomycosis
Interventions
Luliconazole Solution, 10%, Vehicle Solution
Drug
Lead sponsor
Topica Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 7, 2026, 1:40 AM EDT